ASSURE: Seladelpar Achieves Clinical Improvement in Primary

Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.

Related Keywords

, University Of Miami , Drug Administration , Schiff Center , Cynthia Levy , Digestive Disease Week , Liver Diseases , Gamma Glutamyl Transferase , Alanine Transaminase , Primary Biliary Cholangitis , New Therapeutic , Primary Biliary ,